JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
About this episode
Dr. Jake New and Dr. Umang Swami discuss the primary results of the SURE-01 trial on neoadjuvant sacituzumab in muscle-invasive bladder cancer.
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper " Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial ." LINK TO FULL TRANSCRIPT
More episodes of Journal of Clinical Oncology (JCO) Podcast
- Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
- Phase 2 Study of Multi-Cancer Detection from Breath Samples
- JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
- JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
- JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
- JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
Explore listener stats, chart rankings, contacts and more on the Journal of Clinical Oncology (JCO) Podcast podcast page.